A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo

PHASE2CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

May 6, 2021

Primary Completion Date

May 24, 2022

Study Completion Date

May 24, 2023

Conditions
NonSegmental Vitiligo
Interventions
DRUG

INCB054707

INCB054707 will be administered once daily

DRUG

Placebo

Placebo or INCB054707 will be administered once daily

Trial Locations (31)

19462

Investigative Site 021, Plymouth Meeting

32073

Investigative Site 032, Orange Park

33401

Investigative Site 011, West Palm Beach

33613

Investigative Site 005, Tampa

33614

Investigative Site 022, Tampa

35244

Investigative Site 010, Hoover

37130

Investigative Site 004, Murfreesboro

43215

Investigative Site 003, Columbus

55112

Investigative Site 023, Saint Paul

70433

Investigative Site 024, Covington

73071

Investigative Site 007, Norman

75230

Investigative Site 033, Dallas

78213

Investigative Site 012, San Antonio

85260

Investigative Site 028, Scottsdale

85295

Investigative Site 015, Gilbert

90036

Investigative Site 009, Los Angeles

90045

Investigative Site 018, Los Angeles

92697

Investigative Site 006, Irvine

95815

Investigative Site 017, Sacramento

97223

Investigative Site 001, Portland

99202

Investigative Site 030, Spokane

02135

Investigative Site 002, Brighton

07044

Investigative Site 027, Verona

R3M 3Z4

Investigative Site 020, Winnipeg

M8X 1Y9

Investigative Site 014, Etobicoke

N6H 5LR

Investigative Site 034, London

L5H 1G9

Investigative Site 025, Mississauga

M2M4J5

Investigative Site 026, North YORK

L6J 7W5

Investigative Site 031, Oakville

K9J 5K2

Investigative Site 008, Peterborough

Q1V 4X7

Investigative Site 029, Québec

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Incyte Corporation

INDUSTRY